info@biomedres.us   +1 (720) 414-3554   600 Third Avenue, 2nd floor, New York - 10016, USA
ISSN: 2574 -1241
Impact Factor 0.548

EditorialOpen Access

Cancer Associated Thrombosis: Still many unanswered Questions

Volume 4 - Issue 3

Nahla AM Hamed*

  • Author Information Open or Close
    • Department of Hematology, Alexandria University, Egypt

    *Corresponding author:Nahla AM Hamed, Professor of Hematology, Hematology Department, Faculty of Medicine, Alexandria University, Egypt, Tel: 01223597914 ; Email: drhamedn@hotmail.com

Received: May 07, 2018;   Published: May 14,2018

DOI: 10.26717/BJSTR.2018.04.0001066

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

LMWH is recommended by major consensus guidelines for both initial and long-term anticoagulation in cancer-associated thrombosis. With improvements in imaging technology and extended survival duration of cancer patients, more unique challenges are encountering. These include optimal duration of anticoagulant therapy, management of incidental VTE, identifying biomarkers that can predict recurrent VTE, treatment of recurrent VTE after initial therapy, the treatment of patients with concurrent bleeding or those at a high risk of bleeding, management of VTE in intracranial malignancies and the limitations of the novel direct oral anticoagulants.

Abbreviation: VTE: Venous Thromboembolism; PE: Pulmonary Embolism; DOACs: Direct Oral Anticoagulants; LMWH: Low-Molecular-Weight Heparin; UFH: Un-Fractionated Heparin; CrCl: Creatinine Clearance; INR: International Normalized Ratio; ASCO: American Society of Clinical Oncology; FDA: Food and Drug Administration; VKAs: Vitamin K Antagonists; HIT: Heparin-Induced Thrombocytopenia.

Abstract| Introduction| Conclusion| References|